List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
In this Q&A, we speak to Dr Emma Murphy, Head of Biology at the Alzheimer’s Research UK Oxford Drug Discovery Institute. Among her many insights, she discusses how the challenges in developing reproducible assays can be addressed, as well as strategies used to translate promising findings into clinically relevant tools…
A new method for a fragmentation-based identification of lipids could enable the study of cancer cells in detail not seen before.
In this article, Dr Robert Scoffin, Chairman and CEO at Cresset, explores FEP and its current challenges, and outlines how continuous advancements and strategic approaches are helping to drive the adoption of FEP methods in drug discovery.
Lidia Pieri earned a Master’s degree with honours in high energy physics at CERN, a PhD in theoretical astroparticle physics from Rome-3 (Italy) and an Executive MBA in Business Innovation with honours from the MIB school in Trieste. During the academic period she gained international exposure and recognition working as…
The compound 11c demonstrates an excellent safety profile and is an exciting advancement in liver disease management.
Six molecules that had potent antibacterial effect against one of the world’s most dangerous antibiotic-resistant bacteria were generated.
In this Q&A, Dr Vidmantas Šakalys, CEO of Vital3D, provides insights into the potential of 3D bioprinting to revolutionise the traditional drug development process, facilitating more accurate models and limiting the use of animal testing.
A condensed version of the SMN2 gene could improve discovery of potential therapies for spinal muscular atrophy and other conditions.
Introducing Kratherine Tan! Katherine joined the SCIEX team with a strong desire to further the company’s mission of delivering solutions to advance human wellness. Her main area of interest is within mass spectrometry-based proteomics from which she has accumulated a wealth of knowledge and experience in this space over the…
After gaining her PhD in Biophysics as an International Max-Planck Research School scholar, Leila joined the nuclear field in 2006, starting as an engineer in radiation protection and neutron fluence. Throughout Leila’s career, she has worked across multiple disciplines as a technical project lead in nuclear engineering, lastly in the…
28 February 2024 | By Eurofins DiscoverX
Join the webinar to learn about recently published research toward the advancement of non-opioid analgesics targeting the Nav1.8 ion channel, a validated pain target primarily found in peripheral nociceptors.
Gamma delta (γδ) T cells comprise a distinct and powerful subpopulation of T cells, bridging innate and adaptive immunity, that holds great promise for treating cancer. IN8Bio co-founder and CEO William Ho and COO Kate Rochlin discuss what makes γδ T cells unique, how preclinical research suggests their antitumour activity…
Introducing Dr Beate Mueller-Tiemann, whose journey spans continents and disciplines, with a passion for biochemistry and molecular biology since her high school days. From elucidating pivotal proteins in cancer to monoclonal antibody discovery, Dr Mueller-Tiemann's contributions have not only transformed our understanding of diseases but have also fuelled research in…
A new study proves that organoid drug testing is highly accurate at predicting effective treatments and finds a novel therapeutic option.
The computer model enables a better understanding of how drugs affect fibroblasts and finds a promising candidate to prevent heart scarring.
